## WHAT IS CLAIMED IS:

- A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting an immune response with an immunologically effective amount of a composition
  comprising a phosphatidylserine/ polypeptide conjugate.
  - 2. The method of claim 1, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
- 10 3. The method of claim 1, wherein said cancer cell is comprised within an animal.
  - 4. The method of claim 3, wherein said animal is a human.
- 5. The method of claim 1, wherein said composition further comprises a 15 pharmaceutical excipient.
  - 6. The method of claim 5, wherein said composition is administered to said human topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.
- The method of claim 1, wherein said polypeptide is selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and β<sub>2</sub>-glycoprotein I.
  - 8. The method of claim 7, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
- 25 9. A method for treating cancer comprising eliciting an immune response with an immunologically effective amount of a composition comprising a phosphatidylserine/ polypeptide conjugate.
- 10. A method for treating cancer comprising contacting a subject with a lipid or 30 lipid/polypeptide conjugate effective to treat said cancer.

15

- 11. The method of claim 8, wherein said lipid is phosphatidylcholine or phosphatidylserine.
- 5 12. A method of generating an immune response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.
- 10 13. A method of making an antibody that specifically binds to phosphatidylserine, a phosphatidylcholine/polypeptide conjugate or a phosphatidylserine/polypeptide conjugate, said method comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.
  - 14. The method of claim 13, wherein a composition comprising phosphatidylserine/BSA, phosphatidylserine/KLH, phosphatidylserine/BGG, or phosphatidylserine/β<sub>2</sub>-glycoprotein I conjugate is administered to the animal.
- phosphatidylserine specifically binds to 20 15. An antibody that phosphatidylcholine/polypeptide conjugate or a phosphatidylserine/polypeptide conjugate, said antibody made by a process comprising administering to an animal a pharmaceutical of a immunologically effective amount composition comprising an conjugate phosphatidylserine/polypeptide phosphatidylcholine/polypeptide or a composition. 25
  - 16. The antibody of claim 15, wherein a composition comprising phosphatidylserine/BSA, phosphatidylserine/KLH, phosphatidylserine/BGG, or phosphatidylserine/ $\beta_2$ -glycoprotein I conjugate is administered to the animal

20

25

30

- 17. The antibody of claim 16, wherein said polypeptide is  $\beta_2$ -glycoprotein I.
- 18. The antibody of claim 15, wherein the antibody is linked to a detectable label.
- 5 19. The antibody of claim 18, wherein the antibody is linked to a radioactive label, a fluorogenic label, a nuclear magnetic spin resonance label, biotin or an enzyme that generates a detectable product upon contact with a chromogenic substrate.
- 20. The antibody of claim 18, wherein the antibody is linked to an alkaline phosphatase, 10 hydrogen peroxidase or glucose oxidase enzyme.
  - 21. The antibody of claim 15, wherein the antibody is a monoclonal antibody.
- 22. A method for detecting a phosphatidylserine, phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate in a biological sample, comprising the steps of:
  - (a) obtaining a biological sample suspected of containing a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate;
  - (b) contacting said sample with a first antibody that binds to a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate, under conditions effective to allow the formation of immune complexes; and
    - (c) detecting the immune complexes so formed.
  - 23. An immunodetection kit comprising, in suitable container means, an antibody that specifically binds to phosphatidylserine or to a phosphatidylserine/polypeptide conjugate, and an immunodetection reagent.

- 24. The immunodetection kit of claim 23, wherein the immunodetection reagent is a detectable label that is linked to said conjugate or said antibody.
- 5 25. The immunodetection kit of claim 23, wherein the immunodetection reagent is a detectable label that is linked to a second antibody that has binding affinity for said conjugate or said first antibody.
- 26. A method for treating cancer in an animal comprising generating in said animal an 10 immune response to a composition comprising a phosphatidylserine or phosphatidylserine/polypeptide conjugate effective to treat said cancer.
- 27. The method of claim 26, wherein the composition comprises a phosphatidylserine/ polypeptide conjugate comprising a polypeptide selected from the group consisting of
  15 BSA, KLH, BGG, diphtheria toxin, and β<sub>2</sub>-glycoprotein I.